Results 291 to 300 of about 240,256 (373)

Subcutaneous Foslevodopa as Novel Rescue Therapy for Akinetic Crisis in Parkinson's Disease: A Case Report

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Bendix Labeit   +3 more
wiley   +1 more source

Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments

open access: yesMed Research, EarlyView.
ABSTRACT The immune microenvironment includes immune cells, cytokines, extracellular matrix, vesicles, etc. The interactions between these components form a unique local immune microecology. Although immunity serves as the defense against external pathogens, aberrant immune activation often contributes to disease development.
Guoqing Li   +13 more
wiley   +1 more source

Serotonergic dysfunction in patients with impulse control disorders in Parkinson's disease. [PDF]

open access: yesBrain
Prange S   +11 more
europepmc   +1 more source

Interpersonal Psychotherapy for the Treatment of Depression in Parkinson's Disease: Results of a Randomized Controlled Trial

open access: yesMovement Disorders, EarlyView.
Abstract Background Depression is a common nonmotor complication in Parkinson's disease (PD). However, few studies have evaluated the efficacy of first‐line psychological therapies for depression in this patient population. Objectives This randomized controlled trial evaluated the efficacy of interpersonal psychotherapy (IPT), an empirically validated ...
Diana Koszycki   +5 more
wiley   +1 more source

Treatment Selection and Prioritization for the EJS ACT‐PD MAMS Trial Platform

open access: yesMovement Disorders, EarlyView.
Abstract Background There are currently no disease‐modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT‐PD) initiative will expedite clinical assessment of putative DMTs through a multi‐arm multistage (MAMS) trial, testing several treatments against a common ...
Cristina Gonzalez‐Robles   +29 more
wiley   +1 more source

The manicogenic properties of clozapine: a rare but serious potential adverse effect. [PDF]

open access: yesJ Psychiatry Neurosci
Cholette-Tétrault S   +3 more
europepmc   +1 more source

Neuronal α‐Synuclein Disease Stage Progression over 5 Years

open access: yesMovement Disorders, EarlyView.
Abstract Background Neuronal α‐synuclein disease (NSD) is defined by the presence of an in vivo biomarker of neuronal alpha‐synuclein (n‐asyn) pathology. The NSD integrated staging system (NSD‐ISS) for research describes progression across the disease continuum as stages 0 to 6.
Tanya Simuni   +205 more
wiley   +1 more source

Home - About - Disclaimer - Privacy